News
UBS remains bullish on Eli Lilly’s future thanks to surging demand for its obesity and diabetes treatments. UBS predicts Zepbound sales could exceed market expectations by roughly 15%. Meanwhile, ...
A court-appointed special master recommended a bid backed by Gold Reserve and Koch over a rival hedge-fund offer. Krispy Kreme's top finance executive, Jeremiah Ashukian, is leaving the doughnut maker ...
Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...
Lizzo is giving the people what they want — and that’s the secret to her transformation! On Thursday, July 3, the 37-year-old ...
I’m so happy and proud of what I’ve done and no one can take that away from me,” she captioned the side-by-side mirror ...
VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.
Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...
CVS says the decision to cover Wegovy and exclude Zepbound is "forcing the drug manufacturers to compete with one another" and will encourage both Eli Lilly and Novo Nordisk to lower prices for their ...
Linear relationship seen for waist circumference, BP; reduction in HOMA-IR, hemoglobin A1c seen with modest weight reduction.
A higher proportion of sleep medicine providers vs. patients reported CPAP over tirzepatide as their preferred treatment option for comorbid obesity and obstructive sleep apnea, according to data ...
Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why ...
The Dalai Lama said on Wednesday the institution of the Dalai Lama will continue and the Gaden Phodrang trust has sole ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results